A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Different Concentrations of QLM3004 in Delaying the Progression of Myopia in Children
Latest Information Update: 05 Dec 2023
At a glance
- Drugs QLM-3004 (Primary)
- Indications Myopia
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 05 Dec 2023 New trial record